News stories about Abeona Therapeutics (NASDAQ:ABEO) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Abeona Therapeutics earned a media sentiment score of 0.04 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 49.4690305633996 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Abeona Therapeutics (NASDAQ ABEO) opened at $14.85 on Wednesday. The company has a market cap of $694.61, a price-to-earnings ratio of -22.85 and a beta of 2.34. Abeona Therapeutics has a 1 year low of $4.50 and a 1 year high of $22.75.

Abeona Therapeutics (NASDAQ:ABEO) last posted its earnings results on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.05. The firm had revenue of $0.22 million for the quarter, compared to the consensus estimate of $0.22 million. Abeona Therapeutics had a negative net margin of 2,946.58% and a negative return on equity of 27.69%. equities research analysts anticipate that Abeona Therapeutics will post -0.6 EPS for the current fiscal year.

Several analysts recently issued reports on the company. Cantor Fitzgerald increased their price objective on Abeona Therapeutics from $21.00 to $34.00 and gave the stock an “overweight” rating in a report on Wednesday, October 11th. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective (up from $20.00) on shares of Abeona Therapeutics in a report on Monday, October 9th. Citigroup assumed coverage on Abeona Therapeutics in a report on Tuesday, October 10th. They set a “buy” rating and a $32.00 price objective for the company. ValuEngine lowered Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, Zacks Investment Research lowered Abeona Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, November 23rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company’s stock. Abeona Therapeutics has a consensus rating of “Buy” and a consensus target price of $26.10.

TRADEMARK VIOLATION WARNING: This report was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Insider Buying and Selling by Quarter for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with's FREE daily email newsletter.